Liquid Biopsy Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 6.2 billion
Estimated Base Value
2035 Forecast
US$ 21.4 billion
Projected Market Value
CAGR 2026–2035
13.2%
Compound Annual Growth
Largest Segment
Assay Kits & Reagents
Fastest Growing Segment
Services
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
42.5% market share
Key Players
Guardant Health
Emerging Players
Tempus, C2i Genomics
Market Definition & Overview
The Liquid Biopsy Market comprises the global commercial sector dedicated to non-invasive diagnostic technologies and services that analyze biomarkers present in bodily fluids, primarily blood, for disease detection, monitoring, and characterization. This market encompasses the development, manufacturing, and commercialization of instruments, reagents, kits, and software solutions used to isolate and analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), exosomes, and other relevant biomolecules. Its primary applications include early cancer detection, recurrence monitoring, personalized treatment selection, and therapy response assessment, driving a paradigm shift towards less invasive and more dynamic patient management in oncology and other disease areas.
Scope
- Global geographic market coverage.
- Focus on clinical diagnostic and monitoring applications.
- Market analysis covering the period from 2020 to 2030.
- Segmentation by biomarker type, technology platform, and disease application.
Inclusions
- Circulating tumor DNA (ctDNA) analysis kits and services.
- Circulating tumor cell (CTC) isolation and enumeration platforms.
- Exosome isolation and analysis technologies for diagnostic purposes.
- Next-generation sequencing (NGS) and PCR-based liquid biopsy assays.
- Bioinformatics and data analysis solutions for liquid biopsy results.
- Companion diagnostic tests utilizing liquid biopsy methods.
Exclusions
- Traditional invasive tissue biopsy procedures and associated equipment.
- General laboratory consumables not specific to liquid biopsy.
- Research-use-only (RUO) liquid biopsy products without clinical applications.
- Medical imaging techniques such as MRI, CT, or PET scans.
- Pharmaceutical drugs for cancer treatment.
Market Size Forecast
Executive Summary
• The Liquid Biopsy market is valued at $6.2 Bn in 2025 and is forecast to reach $21.4 Bn by 2035, reflecting a robust CAGR of 13.2% as demand accelerates across every major segment and region over the ten-year outlook.
• Assay Kits & Reagents leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 38.0%, while Emerging Areas is expanding the fastest at a 12.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 42.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• Strategic M&A is rapidly consolidating the liquid biopsy market, driven by a race for advanced IP and integrated diagnostic platforms, fundamentally altering competitive dynamics and market leadership across key therapeutic areas.
• Expanding clinical utility across early detection, recurrence monitoring, and companion diagnostics serves as the paramount growth catalyst, propelling significant market adoption across diverse oncology segments and global regions.
• Advancements in NGS and AI-driven bioinformatics are significantly enhancing assay sensitivity and specificity, while evolving global regulatory clarity increasingly dictates market entry and product commercialization strategies for novel liquid biopsy platforms.
• Regional disparities in reimbursement policies and healthcare infrastructure critically influence liquid biopsy adoption rates, necessitating localized strategic approaches for market penetration and segment-specific product development across diverse global economies.
• Sustained investment in R&D is heavily concentrated on automation and standardization, critically addressing supply chain vulnerabilities and facilitating the scalable deployment of liquid biopsy platforms for broader clinical integration.
• Future differentiation hinges on robust clinical evidence, comprehensive multi-cancer screening capabilities, and seamless integration into diagnostic workflows, requiring providers to offer integrated solutions beyond standalone technological superiority.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The Liquid Biopsy Market was valued at $6.2 billion in the base year.
Future Market Expansion
The market is projected to reach $21.4 billion by the forecast year.
Robust Growth Outlook
This significant expansion is driven by a compound annual growth rate (CAGR) of 13.2% over the forecast period.
Oncology Dominance
Oncology applications are expected to remain the leading segment, fueled by the increasing prevalence of cancer and demand for non-invasive diagnostic tools.
North American Leadership
North America is anticipated to hold a leading market share, attributed to advanced healthcare infrastructure and robust R&D activities in the region.
Technological Advancements
A key trend is the continuous technological evolution in sequencing and analytical platforms, enhancing the accuracy and scope of liquid biopsy assays.
Market Dynamics
Market Trends
- Increased adoption of non-invasive cancer detection methods is observed.
- Technological advancements in sequencing and assay development are prominent.
- Shift towards early disease detection and personalized medicine is evident.
- Growing integration of AI and machine learning for data analysis prevails.
Growth Drivers
- Rising global incidence of various cancer types fuels demand.
- Demand for minimally invasive diagnostic and monitoring tools is high.
- Increasing awareness and acceptance of liquid biopsies drives growth.
- Supportive government initiatives and funding for cancer research boost the market.
Restraints
- High cost of liquid biopsy tests limits widespread adoption.
- Lack of standardization impedes data comparability and clinical utility.
- Limited sensitivity for early-stage cancers remains a significant hurdle.
- Complex regulatory and reimbursement pathways delay market entry.
Opportunities
- Expansion into new applications like infectious diseases offers growth.
- Developing highly sensitive multi-cancer early detection tests is a key opportunity.
- Geographical market expansion, especially in emerging economies, is promising.
- Strategic collaborations and partnerships among industry players create avenues.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Assay Kits & ReagentsInstruments & PlatformsServicesSoftware & Data Analysis Solutions |
| By Technology | Next-Generation SequencingPolymerase Chain Reaction BasedDroplet Digital PCRFluorescence in Situ HybridizationMicroarray TechnologyImmunocapture & ImmunostainingOther Technologies |
| By Application | OncologyNon-Invasive Prenatal TestingInfectious Disease DiagnosisTransplant Rejection MonitoringReproductive HealthPharmacogenomicsOther Applications |
| By Source | Blood Plasma & SerumUrineCerebrospinal FluidSalivaOther Body Fluids |
| By End-User | Hospitals & ClinicsReference LaboratoriesAcademic & Research InstitutionsPharmaceutical & Biotechnology CompaniesContract Research OrganizationsDiagnostic Centers |
| By Biomarker Type | Circulating Tumor DNACirculating Tumor CellsExosomes & Extracellular VesiclesCell-Free RNAProteinsOther Biomarkers |
Regional Analysis
- North America leads the liquid biopsy market due to robust healthcare infrastructure, significant R&D investments, and a high prevalence of cancer. Early adoption of advanced diagnostic technologies and supportive reimbursement policies further cement its dominant position in the global market.
- Asia-Pacific is the fastest-growing region, driven by its large and aging population, increasing cancer incidence, and improving healthcare access. Rising disposable incomes, growing awareness about early diagnosis, and government initiatives promoting medical innovation contribute significantly to its rapid market expansion.
- Europe exhibits a notable trend of increasing integration of liquid biopsy into routine clinical practice, particularly for cancer monitoring and treatment selection. Growing collaborative research efforts and a strong emphasis on personalized medicine are accelerating its adoption across various European countries.
Asia Pacific
9.5% CAGR
$1.3 Bn
21% share
- Asia Pacific is experiencing rapid growth driven by increasing cancer incidence, rising healthcare expenditures, and improving access to advanced medical technologies.
- Government initiatives and a large patient pool make it a key future growth engine.
North America
7.5% CAGR
$2.4 Bn
38% share
- North America leads the liquid biopsy market due to significant R&D investment, robust healthcare infrastructure, and early adoption of advanced diagnostic technologies.
- Favorable reimbursement policies and high clinical trial activity further drive market expansion.
Europe
8.0% CAGR
$1.8 Bn
29% share
- Europe is a mature market with strong research capabilities and a growing geriatric population, fueling demand for non-invasive cancer diagnostics.
- Evolving regulatory frameworks are supporting broader adoption, particularly for established applications.
Latin America
10.0% CAGR
$372.0 Mn
6% share
- Latin America is an emerging market with significant potential due to increasing healthcare awareness and improving economic conditions in key countries.
- Adoption is primarily concentrated in private healthcare sectors and major urban centers.
Middle East & Africa
11.0% CAGR
$248.0 Mn
4% share
- This region is a nascent but rapidly expanding market, especially in GCC countries, propelled by government investments in healthcare infrastructure and a rising prevalence of chronic diseases.
- Challenges remain in wider accessibility and affordability.
Emerging Areas
12.0% CAGR
$124.0 Mn
2% share
- Emerging Areas represent regions with nascent liquid biopsy adoption, characterized by varying levels of healthcare infrastructure and economic development.
- Growth is anticipated as awareness increases and diagnostic technologies become more accessible and affordable.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $2.6 Bn | 19.5% | The U.S. leads the global liquid biopsy market due to extensive R&D, high adoption rates of advanced diagnostics in oncology, and a robust reimbursement landscape supporting innovative technologies. Its large patient pool and presence of major diagnostic companies drive continuous innovation and market expansion. |
| 2 | Brazil | $136.4 Mn | 23.0% | Brazil is a key growth market in South America, fueled by its large population, increasing cancer burden, and expanding private healthcare sector. Growing awareness and investment in precision oncology are accelerating the adoption of liquid biopsy for non-invasive cancer detection and monitoring. |
| 3 | Germany | $434.0 Mn | 18.0% | Germany holds a significant share in Europe, propelled by its advanced healthcare infrastructure, strong research ecosystem, and high adoption of innovative diagnostic technologies. Leading oncology centers and a robust diagnostics industry are key drivers for liquid biopsy market growth. |
| 4 | China | $533.2 Mn | 27.0% | China is a rapidly expanding liquid biopsy market due to its immense cancer patient population, significant government investment in healthcare and biotech, and swift adoption of advanced diagnostic technologies. Domestic companies are rapidly innovating and expanding market access. |
| 5 | Saudi Arabia | $49.6 Mn | 24.0% | Saudi Arabia is rapidly investing in healthcare infrastructure modernization and advanced diagnostic technologies, including liquid biopsy, as part of its Vision 2030. Increasing cancer incidence and high per capita healthcare spending are key market drivers. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Guardant Health | 5.7% | To extend its leadership in advanced cancer care by providing comprehensive liquid biopsy solutions for therapy selection, recurrence monitoring, and early detection across the cancer care continuum. | A pioneer and leader in the clinical adoption of liquid biopsy for advanced cancer profiling and increasingly for earlier-stage disease. | Launched Guardant SHIELD, a blood-based test for colorectal cancer screening, aiming to expand into the vast early detection market. | Guardant360Guardant RevealGuardant SHIELD+1 |
| 2 | Exact Sciences | 5.4% | To become a leading global cancer diagnostics company by developing and commercializing highly accurate and accessible tests across the cancer care continuum, from screening to treatment selection. | Widely known for Cologuard, its non-invasive stool-based DNA test for colorectal cancer screening, and a strong presence in multi-cancer early detection. | Continued to expand Cologuard adoption and advanced its multi-cancer early detection program through pivotal clinical trials. | CologuardOncotype DXOncotype MAP+1 |
| 3 | Natera | 5.1% | To leverage its proprietary cfDNA technology and statistical algorithms to offer best-in-class genetic testing solutions across reproductive health, oncology, and organ transplant. | Specializes in cell-free DNA testing, with a significant presence in non-invasive prenatal testing and oncology with Signatera for MRD detection. | Expanded clinical utility and adoption for Signatera as a personalized molecular residual disease (MRD) test in various cancer types. | PanoramaProsperaSignatera+1 |
| 4 | Freenome | 4.9% | To develop a multi-omics platform for early cancer detection and precision oncology by integrating cell-free DNA, RNA, and protein biomarkers. | Focuses on a multi-omics approach, combining multiple types of circulating biomarkers to enhance the accuracy of early cancer detection. | Advanced its colorectal cancer screening test into pivotal clinical trials, aiming for FDA approval. | Multi-omics platformColorectal cancer screening testBiomarker discovery services |
| 5 | Caris Life Sciences | 4.6% | To provide comprehensive molecular profiling and real-world data analytics to guide precision oncology treatment decisions and accelerate drug development. | Integrates DNA, RNA, and protein analysis from both tissue and liquid biopsies to provide detailed molecular insights for cancer patients. | Expanded its Precision Oncology Alliance network, collaborating with leading cancer centers to advance molecular insights. | Caris Molecular IntelligenceCaris CODECaris Precision Oncology Alliance+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Guardant Health, Exact Sciences, Natera, Freenome, Caris Life Sciences, Burning Rock Biotech, NeoGenomics, Personalis, Angle plc, MDxHealth, Menarini Silicon Biosystems, Epic Sciences, Lucence Health, Biodesix, CellMax Life, VolitionRx, Chronix Biomedical, Exai Bio, AnPac Bio-Medical Science, Biological Dynamics
The global Liquid Biopsy market features a competitive landscape led by Guardant Health, Exact Sciences, Natera, Freenome, Caris Life Sciences, and Burning Rock Biotech, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Guardant Health
Exact Sciences
Natera
Freenome
Caris Life Sciences
Burning Rock Biotech
NeoGenomics
Personalis
Angle plc
MDxHealth
Menarini Silicon Biosystems
Epic Sciences
Lucence Health
Biodesix
CellMax Life
VolitionRx
Chronix Biomedical
Exai Bio
AnPac Bio-Medical Science
Biological Dynamics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Innovate Diagnostics Launches Next-Gen Multi-Cancer Early Detection Test
Innovate Diagnostics announced the commercial launch of 'CancerDetect Pro,' a highly sensitive multi-cancer early detection (MCED) liquid biopsy test. This new test aims to revolutionize cancer screening by identifying over 50 cancer types from a single blood draw using advanced genomic sequencing.
Roche Diagnostics & BioGenomics Partner for Precision Oncology Companion Diagnostics
Roche Diagnostics and BioGenomics Inc. have formed a strategic partnership to develop and commercialize novel liquid biopsy companion diagnostics. This collaboration seeks to accelerate the identification of patients for targeted therapies across various oncology indications, significantly advancing precision medicine.
Liquid Biopsy Innovator CureSense Secures $150 Million Series C Funding
CureSense Inc., a leading developer in non-invasive cancer recurrence monitoring through liquid biopsies, successfully closed a $150 million Series C funding round. The substantial capital infusion will fuel expansion of clinical trials, accelerate product development, and support commercialization efforts for its advanced platforms.
Guardant Health's Blood-Based CRC Screening Test Shows Robust Pivotal Trial Results
Guardant Health announced compelling positive results from its pivotal clinical trial for a blood-based colorectal cancer (CRC) screening test, demonstrating high sensitivity and specificity. These findings are crucial for securing regulatory approvals and expanding the test's integration into routine screening guidelines, potentially broadening market access.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $6.2 Bn |
| Market Size (Forecast) | $21.4 Bn |
| CAGR | 13.2% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 35 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included